The integration of magnetic resonance imaging (MRI) and linear accelerator (MRLS) aims to completely change the treatment of the central nervous system (CNS) tumor. This cutting -edge method is designed to improve the accuracy of radiation therapy and significantly reduce neurotoxicity by adjusting the treatment plan according to daily anatomical changes. This innovation may change the game of patients with central nervous system tumors, thereby providing them with more personalized and effective therapies.
Researchers at the H. Lee Moffitt Cancer Center and Research Institute led by Dr. John Bryant and Dr. Daniel Oliver explored the potential of MRL in enhancing CNS tumor treatment. Their comments were published in the magazine, emphasizing how MRI’s high -quality soft tissue contrast can help visual tumors and risk organs nearby. This allows real -time adjustment of radiation therapy to ensure accurate dose delivery and minimize damage to healthy tissues.
Dr. Kobe emphasizes the potential of this technology: “MRI provides excellent visualization of central nervous system tumors due to its high -quality soft tissue comparison, so it is crucial to the diagnosis and treatment plan of these malignant tumors.” The adaptive magnetic resonance guidance of radiation therapy (MRGRT) allows clinicians to modify the treatment plan every day based on the latest anatomical data.
The important application of the MRL discussed in the study is to treat glioblastoma (GBM), which is one of the most aggressive brain tumors. By adjusting the treatment plan throughout the treatment, clinicians can explain changes in the size and position of the tumor. A forward -looking study involving a large number of patients with GBM has shown that a large anatomy change has occurred during the treatment process, emphasizing the necessity of adaptive planning to maintain the accuracy and effect of treatment.
In addition, the study discussed the use of MRL in the use of intracranial and spine tumors in the three -dimensional directional radiation therapy (SRT). Compared with conventional methods, the enhanced accuracy provided by MRL guides SRT can reduce the incidence. Feasibility studies have shown that hippocampus avoids the promising results of the whole brain radiation therapy (HA-WBRT), which aims to minimize cognitive side effects and effectively target tumors.
The study also introduced the functions of the two commercially available MRL systems: ViewRay Mridian and Elekta Unity. These systems show the significant improvement of dosage measurement and treatment plans, indicating that while maintaining effective tumor control while reducing the potential of radiation exposure to health tissues.
The ongoing clinical trials emphasized in the study aims to further verify these benefits, hoping to establish MRLS as a standard tool for CNS tumor therapy. Dr. Oliver said: “Our goal is to provide evidence -based support for the widely adopted MRL in clinical practice.”
Looking forward to the future, studies have shown that integrating multi -parameter MRI (MPMRI) and genetic guiding radiation therapy can further improve the accuracy and effectiveness of CNS tumor treatment. These progress is expected to be tailor -made according to the unique biology characteristics of each patient, which may lead to better results.
In short, the integration of MRI and linear accelerator marks the significant improvement of the central nervous system tumor treatment. Dr. Bryant, Dr. Oliver and his colleagues are very optimistic. As the research continues, clinical trials confirm these discoveries, and MRL is expected to become a key tool for combating malignant tumors in the central nervous system.
Journal reference
Kobe, John Michael and others. “The treatment of central nervous system tumors in MR linear accelerator: current practice and future direction review.” Cancer 2023, 15,5200. Doi: https: //doi.org/10.3390/cancers15215200
About the author
Dr. John Michael Bryant He is the chief physician of the H. Lee Moffitt Cancer Center and Institute. Their research focuses on developing and translating advanced technologies to improve the ending of cancer patients, especially radilateral therapy guided by MRI, deep neural networks to predict the deep neural network of clinical results and high-grade nanomaterials for onco-theragnostic applications. Essence In addition to their research, he is also committed to strengthening research and integration in clinical practice. As a co -founder and chairman of the Canopy Cancer Cancer Collection resident and committee, they have coordinated the cooperation research of 14 leading cancer centers. When he transitioned to the meeting, his goal was to continue to use advanced technologies to improve clinical results and promote the field of radiation oncology.
Dr. Daniel Oliver It is a neuroma and assistant members of the Department of Radiation on the Department of Radiation and Cancer Center. Prior to school at the medical school, Dr. Oliver worked at the Conservatory (cello) at the Conservatory of Music (Cello) at the University of Alaska-Form Bank and Emery University. He obtained a doctorate degree in medical science from the University of Medicine at the University of Emeri, and completed the radiation tumor residence at the University of Morfi’s Cancer Center/South Florida. Dr. Oliver’s clinical interests are patients with three -dimensional orientation and conventional radiation therapy to treat patients with primary and metastatic tumors in the brain and spine. His research interests are concentrated on improving the results of early metastatic diseases through multi -disciplinary treatment methods and advanced radiation therapy technology.
Ajay doniparthi It is a four -year medical student at the University of South Florida. He grew up in Brookfield in Wisconsin and received a bachelor’s degree in science in biomedicine engineering at the University of Miami. He then completed a master’s degree in science focusing on transforming biomedical engineering at Northwestern University. He spent some time in Baxter’s engineering intern and completed the R & D project of dialysis and disposable medical equipment departments. Ajie is currently engaged in vascular surgery. With the beginning of the clinical journey, he was glad to explore the new boundary of the medical field and eventually transformed these discovers into tangible progress, which had a positive impact on the results of the patient.
Dr. Stephen Rosenberg He is the director of MRI instructing radiation therapy and the deputy member of the MOFFITT Cancer Center of the Department of Radiopathic oncology. He grew up in Medford, New Jersey and obtained a bachelor’s degree in biology at Brown University. He won a master’s degree in clinical and transformation research at Rutgers University and obtained a medical degree. During the medical school, he was appointed researcher at Howard Hughes Medical College. He continued to complete a medical internship at the Sloan Kettering Cancer Center, where he was appointed as an intern at the annual Suzanne Munson. He completed the residence of radiation oncology at the University of Wisconsin, where he was also the chief resident. Dr. Rosenberg’s clinical focus is to treat patients with malignant tumors in thoracic cavity. He is interested in combining radiation with immune regulation drugs and targeting therapies to improve prognosis. Dr. Rosenberg also pays special attention to the research of Mili guiding radiation. He is interested in using radiology and genomics as part of the research work. His work is part of the research plan of the fortress (the future of radiation therapy) departments. It aims to use novel methods to personalized radiation therapy to improve the local control of the tumor and reduce the side effects of patients.
